287 related articles for article (PubMed ID: 26956144)
21. A French family with Charcot-Marie-Tooth disease related to simultaneous heterozygous MFN2 and GDAP1 mutations.
Vital A; Latour P; Sole G; Ferrer X; Rouanet M; Tison F; Vital C; Goizet C
Neuromuscul Disord; 2012 Aug; 22(8):735-41. PubMed ID: 22546700
[TBL] [Abstract][Full Text] [Related]
22. Phenotype of Charcot-Marie-Tooth disease Type 2.
Bienfait HM; Baas F; Koelman JH; de Haan RJ; van Engelen BG; Gabreëls-Festen AA; Ongerboer de Visser BW; Meggouh F; Weterman MA; De Jonghe P; Timmerman V; de Visser M
Neurology; 2007 May; 68(20):1658-67. PubMed ID: 17502546
[TBL] [Abstract][Full Text] [Related]
23. Late-onset hereditary sensory and autonomic neuropathy expands the phenotypic spectrum of MFN2-related diseases.
Wu R; Fu J; Meng L; Lv H; Wang Z; Yuan Y
Neuropathology; 2018 Oct; 38(5):463-467. PubMed ID: 30011089
[TBL] [Abstract][Full Text] [Related]
24. Homozygous Mutations in
Asif M; Chiou CC; Hussain MF; Hussain M; Sajid Z; Gulsher M; Raheem A; Khan A; Nasreen N; Kloczkowski A; Hassan M; Iqbal F; Chen CC
DNA Cell Biol; 2023 Nov; 42(11):697-708. PubMed ID: 37797217
[TBL] [Abstract][Full Text] [Related]
25. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2.
Verhoeven K; Claeys KG; Züchner S; Schröder JM; Weis J; Ceuterick C; Jordanova A; Nelis E; De Vriendt E; Van Hul M; Seeman P; Mazanec R; Saifi GM; Szigeti K; Mancias P; Butler IJ; Kochanski A; Ryniewicz B; De Bleecker J; Van den Bergh P; Verellen C; Van Coster R; Goemans N; Auer-Grumbach M; Robberecht W; Milic Rasic V; Nevo Y; Tournev I; Guergueltcheva V; Roelens F; Vieregge P; Vinci P; Moreno MT; Christen HJ; Shy ME; Lupski JR; Vance JM; De Jonghe P; Timmerman V
Brain; 2006 Aug; 129(Pt 8):2093-102. PubMed ID: 16714318
[TBL] [Abstract][Full Text] [Related]
26. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations.
Calvo J; Funalot B; Ouvrier RA; Lazaro L; Toutain A; De Mas P; Bouche P; Gilbert-Dussardier B; Arne-Bes MC; Carrière JP; Journel H; Minot-Myhie MC; Guillou C; Ghorab K; Magy L; Sturtz F; Vallat JM; Magdelaine C
Arch Neurol; 2009 Dec; 66(12):1511-6. PubMed ID: 20008656
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.
Franco A; Dang X; Zhang L; Molinoff PB; Dorn GW
J Pharmacol Exp Ther; 2022 Nov; 383(2):137-148. PubMed ID: 36507849
[TBL] [Abstract][Full Text] [Related]
28. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene.
Lawson VH; Graham BV; Flanigan KM
Neurology; 2005 Jul; 65(2):197-204. PubMed ID: 16043786
[TBL] [Abstract][Full Text] [Related]
29. A novel mutation of the MFN2 gene in a Chinese family with Charcot-Marie-Tooth disease.
Wang YW; Han WT; Jiang M; Lu CX; Li XF; Zhang X; Li JX
Genet Mol Res; 2012 May; 11(2):1454-9. PubMed ID: 22653593
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the mitofusin 2 R94W mutation in a knock-in mouse model.
Strickland AV; Rebelo AP; Zhang F; Price J; Bolon B; Silva JP; Wen R; Züchner S
J Peripher Nerv Syst; 2014 Jun; 19(2):152-64. PubMed ID: 24862862
[TBL] [Abstract][Full Text] [Related]
31. Acute optic neuropathy associated with a novel MFN2 mutation.
Leonardi L; Marcotulli C; Storti E; Tessa A; Serrao M; Parisi V; Santorelli FM; Pierelli F; Casali C
J Neurol; 2015 Jul; 262(7):1678-80. PubMed ID: 25957633
[TBL] [Abstract][Full Text] [Related]
32. Late onset CMT2A in a Family with an MFN2 Variant: c.2222T>G (p.Leu741Trp).
Lin HP; Ho KWD; Jerath NU
J Neuromuscul Dis; 2019; 6(2):259-261. PubMed ID: 31127728
[TBL] [Abstract][Full Text] [Related]
33. MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives.
Stuppia G; Rizzo F; Riboldi G; Del Bo R; Nizzardo M; Simone C; Comi GP; Bresolin N; Corti S
J Neurol Sci; 2015 Sep; 356(1-2):7-18. PubMed ID: 26143526
[TBL] [Abstract][Full Text] [Related]
34. Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease.
Hikiami R; Yamashita H; Koita N; Jingami N; Sawamoto N; Furukawa K; Kawai H; Terashima T; Oka N; Hashiguchi A; Takashima H; Urushitani M; Takahashi R
J Hum Genet; 2018 Jan; 63(1):89-92. PubMed ID: 29215088
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial dynamics and inherited peripheral nerve diseases.
Pareyson D; Saveri P; Sagnelli A; Piscosquito G
Neurosci Lett; 2015 Jun; 596():66-77. PubMed ID: 25847151
[TBL] [Abstract][Full Text] [Related]
36. MFN2-related Charcot-Marie-Tooth Disease with Atypical Ocular Manifestations.
Nan H; Hata T; Fukao T; Fukao T; Chen W; Kurita T; Natori T; Takiyama Y
Intern Med; 2021 Dec; 60(24):3969-3974. PubMed ID: 34121014
[TBL] [Abstract][Full Text] [Related]
37. Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2.
McCorquodale DS; Montenegro G; Peguero A; Carlson N; Speziani F; Price J; Taylor SW; Melanson M; Vance JM; Züchner S
J Neurol; 2011 Jul; 258(7):1234-9. PubMed ID: 21258814
[TBL] [Abstract][Full Text] [Related]
38. MFN2 deletion of exons 7 and 8: founder mutation in the UK population.
Carr AS; Polke JM; Wilson J; Pelayo-Negro AL; Laura M; Nanji T; Holt J; Vaughan J; Rankin J; Sweeney MG; Blake J; Houlden H; Reilly MM
J Peripher Nerv Syst; 2015 Jun; 20(2):67-71. PubMed ID: 26114802
[TBL] [Abstract][Full Text] [Related]
39. Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses.
Lv H; Wang L; Li W; Qiao X; Li Y; Wang Z; Yuan Y
Clin Neuropathol; 2013; 32(1):16-23. PubMed ID: 22762946
[TBL] [Abstract][Full Text] [Related]
40. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
Baloh RH; Schmidt RE; Pestronk A; Milbrandt J
J Neurosci; 2007 Jan; 27(2):422-30. PubMed ID: 17215403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
